109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
阿奇霉素通过调节 FOXO3A/CCND1 信号通路减轻烟草烟雾诱导的肺衰老
Authors Chen Z, He Q, Yi X, Li T, Wei X , Chen Q, Ning R, Liang H, He Z
Received 11 June 2025
Accepted for publication 29 October 2025
Published 11 November 2025 Volume 2025:20 Pages 3631—3645
DOI https://doi.org/10.2147/COPD.S534997
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Jill Ohar
Zhangrong Chen,1,* Qiaoli He,1,* Xiaofei Yi,2 Tingting Li,3 Xuan Wei,4 Quanfang Chen,1 Ruiling Ning,5 Hanlin Liang,1 Zhiyi He1
1Department of Respiratory and Critical Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of China; 2Department of Respiratory and Critical Care, Chengdu Third People’s Hospital, Chengdu, Sichuan, 610014, People’s Republic of China; 3Ningxia Medical University General Hospital, Ningxia, Yinchuan, 750004, People’s Republic of China; 4Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, 545005, People’s Republic of China; 5Department of Medical Oncology of Respiratory, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530012, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Zhiyi He, Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, No. 6 Shuang Yong Road, Nanning, Guangxi, 530021, People’s Republic of China, Tel +86 187 7801 7698, Email zhiyi-river@163.com
Introduction: Accelerated lung aging is observed in chronic obstructive pulmonary disease (COPD), this study delved into the precise mechanisms through which azithromycin mitigated lung aging associated with COPD.
Methods: Employing network pharmacology, we predicted potential pathways through which azithromycin might affect COPD development. We collected lung tissues from non-smoking individuals, smokers with normal lung function, and smokers with COPD. COPD models were created by exposing mice to cigarette smoke (CS) for 24 weeks and stimulating human bronchial epithelial cells (BEAS-2B) with 0.2% cigarette smoke extract (CSE) for 24 hours. Azithromycin was then given to CS-exposed emphysema mice. BEAS-2B cells were pre-treated with azithromycin before being exposed to CSE and JY-2, a Forkhead box O3 (FOXO3A) inhibitor. Senescence-associated secretory phenotype (SASP) cytokines (interleukin-6, interleukin-8) in mouse BALF were quantified using ELISA. Markers associated with cellular aging (β-galactosidase activity, p53, and p21), FOXO3A, and Cyclin D1 (CCND1) were assessed via qPCR, Western blot, immunohistochemistry, and β-galactosidase staining.
Results: COPD patients who smoked showed increased pulmonary expression of CCND1, p53, and p21, with decreased FOXO3A in comparison with other groups. Similarly, CS-exposed mouse lung tissue exhibited reduced FOXO3A and elevated p53, p21, and CCND1, along with higher SASP secretion in BALF. Azithromycin treatment lowered SASP secretion and decreased CCND1, p53, and p21 expression, while increasing FOXO3A. In BEAS-2B cells, CSE and JY-2 stimulation raised senescence markers and CCND1 while lowering FOXO3A. Azithromycin preconditioning reduced p53, p21, and CCND1 expression and increased FOXO3A.
Conclusion: Azithromycin demonstrated anti-aging properties and modulated lung senescence in COPD via the FOXO3A/CCND1 pathway, presenting fresh insights for the treatment of COPD.
Keywords: azithromycin, COPD, cigarette smoke, senescence, FOXO3A/CCND1 pathway
1Department of Respiratory and Critical Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, People’s Republic of China; 2Department of Respiratory and Critical Care, Chengdu Third People’s Hospital, Chengdu, Sichuan, 610014, People’s Republic of China; 3Ningxia Medical University General Hospital, Ningxia, Yinchuan, 750004, People’s Republic of China; 4Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, 545005, People’s Republic of China; 5Department of Medical Oncology of Respiratory, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, 530012, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Zhiyi He, Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, No. 6 Shuang Yong Road, Nanning, Guangxi, 530021, People’s Republic of China, Tel +86 187 7801 7698, Email zhiyi-river@163.com
Introduction: Accelerated lung aging is observed in chronic obstructive pulmonary disease (COPD), this study delved into the precise mechanisms through which azithromycin mitigated lung aging associated with COPD.
Methods: Employing network pharmacology, we predicted potential pathways through which azithromycin might affect COPD development. We collected lung tissues from non-smoking individuals, smokers with normal lung function, and smokers with COPD. COPD models were created by exposing mice to cigarette smoke (CS) for 24 weeks and stimulating human bronchial epithelial cells (BEAS-2B) with 0.2% cigarette smoke extract (CSE) for 24 hours. Azithromycin was then given to CS-exposed emphysema mice. BEAS-2B cells were pre-treated with azithromycin before being exposed to CSE and JY-2, a Forkhead box O3 (FOXO3A) inhibitor. Senescence-associated secretory phenotype (SASP) cytokines (interleukin-6, interleukin-8) in mouse BALF were quantified using ELISA. Markers associated with cellular aging (β-galactosidase activity, p53, and p21), FOXO3A, and Cyclin D1 (CCND1) were assessed via qPCR, Western blot, immunohistochemistry, and β-galactosidase staining.
Results: COPD patients who smoked showed increased pulmonary expression of CCND1, p53, and p21, with decreased FOXO3A in comparison with other groups. Similarly, CS-exposed mouse lung tissue exhibited reduced FOXO3A and elevated p53, p21, and CCND1, along with higher SASP secretion in BALF. Azithromycin treatment lowered SASP secretion and decreased CCND1, p53, and p21 expression, while increasing FOXO3A. In BEAS-2B cells, CSE and JY-2 stimulation raised senescence markers and CCND1 while lowering FOXO3A. Azithromycin preconditioning reduced p53, p21, and CCND1 expression and increased FOXO3A.
Conclusion: Azithromycin demonstrated anti-aging properties and modulated lung senescence in COPD via the FOXO3A/CCND1 pathway, presenting fresh insights for the treatment of COPD.
Keywords: azithromycin, COPD, cigarette smoke, senescence, FOXO3A/CCND1 pathway